Researchers examined recent studies exploring neuroimaging modalities aided by advanced machine learning (ML) algorithms.
Revolution Medicines’ RAS inhibitor shows promise in early-stage pancreatic cancer trial
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS